Long-Acting Calcium Antagonists in Patients with Coronary Artery Disease: A Meta-Analysis

被引:29
作者
Bangalore, Sripal
Parkar, Sanobar
Messerli, Franz H. [1 ]
机构
[1] St Lukes Roosevelt Hosp, Div Cardiol, Hypertens Program, Dept Med, New York, NY 10019 USA
关键词
Calcium channel blockers; Coronary artery disease; Long-acting; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; CONGESTIVE-HEART-FAILURE; STABLE ANGINA; CARDIOVASCULAR EVENTS; CHANNEL BLOCKER; CLINICAL EVENTS; HYPERTENSIVE PATIENTS; NIFEDIPINE; MORTALITY;
D O I
10.1016/j.amjmed.2008.09.043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The use of calcium channel blockers (CCBs) in patients with coronary artery disease remains controversial, with reports of increased risk of myocardial infarction and all-cause mortality. Short-acting CCBs have an unfavorable hemodynamic profile. The role of long-acting CCBs in patients with coronary artery disease is unknown. METHODS: MEDLINE/CENTRAL/EMBASE database were searched from 1966 to August 2008 for randomized controlled trials of long-acting CCBs in patients with coronary artery disease with follow-up for at least 1 year. We extracted from the studies the baseline characteristics and 6 outcomes: all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, stroke, angina pectoris, and heart failure. RESULTS: Of the 100 randomized controlled trials of CCBs in patients with coronary artery disease, 15 studies evaluating 47,694 patients fulfilled our inclusion criteria. When compared with the comparison group (including placebo), CCBs were not associated with an increased risk of all-cause mortality (relative risk [RR] 0.99; 95% confidence interval [CI], 0.94-1.05), cardiovascular mortality (RR 1.03; 95% CI, 0.95-1.11), nonfatal myocardial infarction (RR 0.96; 95% CI, 0.87-1.06), or heart failure (RR 0.86; 95% CI, 0.71-1.05), and with a 21% reduction in the risk of stroke (95% CI, 0.70-0.89) and 18% reduction in the risk of angina pectoris (95% CI, 0.72-0.94). When compared with placebo, CCBs resulted in a 28% reduction in the risk of heart failure (95% CI, 0.73-0.92). The results were similar for both dihydropyridines and nondihydropyridine CCBs. CONCLUSIONS: In patients with coronary artery disease, long-acting CCBs (either dihydropyridines or nondihydropyridines), were associated with a reduction in the risk of stroke, angina pectoris, and heart failure, with similar outcomes for other cardiovascular events as the comparison group. (C) 2009 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2009) 122, 356-365
引用
收藏
页码:356 / 365
页数:10
相关论文
共 31 条
[1]  
[Anonymous], 1998, STATA TECHNICAL B RE
[2]  
Berenson Alex, 2005, NY TIMES 1114
[3]   Evaluation of the effect of oral verapamil on clinical outcome and angiographic -: Restenosis after percutaneous coronary intervention -: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial [J].
Bestehorn, HP ;
Neumann, FJ ;
Büttner, HJ ;
Betz, P ;
Stürzenhofecker, P ;
von Hodenberg, E ;
Verdun, A ;
Levai, L ;
Monassier, JP ;
Roskamm, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2160-2165
[4]   Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril - V-HeFT III [J].
Cohn, JN ;
Ziesche, S ;
Smith, R ;
Anand, I ;
Dunkman, WB ;
Loeb, H ;
Cintron, G ;
Boden, W ;
Baruch, L ;
Rochin, P ;
Loss, L .
CIRCULATION, 1997, 96 (03) :856-863
[5]  
Dargie HJ, 1996, EUR HEART J, V17, P104
[6]   Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study [J].
Dens, JA ;
Desmet, WJ ;
Coussement, P ;
De Scheerder, IK ;
Kostopoulos, K ;
Kerdsinchai, P ;
Supanantaroek, C ;
Piessens, JH .
HEART, 2003, 89 (08) :887-892
[7]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[8]   NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE [J].
FURBERG, CD ;
PSATY, BM ;
MEYER, JV .
CIRCULATION, 1995, 92 (05) :1326-1331
[9]   A NOTE ON GRAPHICAL PRESENTATION OF ESTIMATED ODDS RATIOS FROM SEVERAL CLINICAL-TRIALS [J].
GALBRAITH, RF .
STATISTICS IN MEDICINE, 1988, 7 (08) :889-894
[10]   DILTIAZEM INCREASES LATE-ONSET CONGESTIVE-HEART-FAILURE IN POSTINFARCTION PATIENTS WITH EARLY REDUCTION IN EJECTION FRACTION [J].
GOLDSTEIN, RE ;
BOCCUZZI, SJ ;
CRUESS, D ;
NATTEL, S .
CIRCULATION, 1991, 83 (01) :52-60